Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metarrestin in Metastatic Solid Tumors
NCT04222413Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2020
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of Metarrestin in solid tumor, pancreatic cancer (PC), breast cancer and 2 more (2 arms), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 28 days and Objective Response Rate. Started Oct 2020; status: recruiting.
02
Drugs
Metarrestin
03
Conditions
solid tumorpancreatic cancer (PC)breast cancercolorectal cancer (CRC)malignant peripheral nerve sheath tumor (MPNST)
Beyond the preview
Go deeper on NCT04222413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04222413.